1. Oct 26, 2020

    Long-term data demonstrates sustained response with teprotumumab for thyroid eye disease

    Long-term clinical trial follow-up data showed a sustained response up to 1 year following treatment for thyroid eye disease (TED) with Tepezza (teprotumumab-trbw; Horizon Therapeutics plc), according to new data presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2020 Virtual Meeting.

    At week 24 of the clinical trials, Tepezza showed clinically significant improvements in pr…

Subscribe

VIDEOS

  • Oct 14, 2020

What is DME?

Conference Roundup

  1. Oct 26, 2020

Long-term data demonstrates sustained response with teprotumumab for thyroid eye disease

Long-term clinical trial follow-up data showed a sustained response up to 1 year following treatment for thyroid eye disease (TED) with Tepezza (teprotumumab-trbw; Horizon Therapeutics plc), according to new data presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2020 Virtual Meeting…

View All

Journal Scan

  1. Oct 22, 2020

Milder clinical manifestations found in pediatric thyroid eye disease

Recognizing subtle clinical differences between adult and pediatric patients with thyroid eye disease (TED) will help clinicians manage cases more effective, according to a study.

In this retrospective case series, 19 patients with pediatric TED…

View All

 


Resources